Can your DNA predict weight loss success? new study tests contrave

NCT ID NCT05919797

Recruiting now Disease control Sponsor: Columbia University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study investigates whether certain genetic variations influence how much weight people lose when taking the FDA-approved weight loss drug Contrave (naltrexone/bupropion). Over 40 weeks, 120 adults with obesity will first follow a calorie-restricted diet for 12 weeks, then add Contrave for 28 weeks. Researchers will analyze DNA to see if specific gene variants are linked to greater weight loss, aiming to personalize obesity treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Naltrexone-Bupropion (Contrave)
What this could lead to: If successful, this could help doctors predict who will lose the most weight with Contrave based on their genes, making weight loss treatment more personalized.
What could go wrong: This is a small, early-phase study (120 people) focused on genetic links, not a direct test of the drug's effectiveness. Results may not apply to everyone, and weight loss varies widely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.